On Friday, Denali Therapeutics Inc (NASDAQ: DNLI) opened lower -3.98% from the last session, before settling in for the closing price of $21.59. Price fluctuations for DNLI have ranged from $14.56 to $33.33 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 350.08% over the past five years. Company’s average yearly earnings per share was noted -162.11% at the time writing. With a float of $124.59 million, this company’s outstanding shares have now reached $143.84 million.
Let’s look at the performance matrix of the company that is accounted for 445 employees. In terms of profitability, gross margin is 102.06%, operating margin of 165.42%, and the pretax margin is 140.13%.
Denali Therapeutics Inc (DNLI) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Denali Therapeutics Inc is 13.45%, while institutional ownership is 88.86%. The most recent insider transaction that took place on Jan 06 ’25, was worth 247,796. In this transaction Chief Medical Officer of this company sold 12,255 shares at a rate of $20.22, taking the stock ownership to the 178,580 shares. Before that another transaction happened on Jan 07 ’25, when Company’s Chief Medical Officer sold 2,907 for $20.81, making the entire transaction worth $60,495. This insider now owns 175,673 shares in total.
Denali Therapeutics Inc (DNLI) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -162.11% per share during the next fiscal year.
Denali Therapeutics Inc (NASDAQ: DNLI) Trading Performance Indicators
Check out the current performance indicators for Denali Therapeutics Inc (DNLI). In the past quarter, the stock posted a quick ratio of 9.98.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.76, a number that is poised to hit -0.80 in the next quarter and is forecasted to reach -2.99 in one year’s time.
Technical Analysis of Denali Therapeutics Inc (DNLI)
Denali Therapeutics Inc (NASDAQ: DNLI) saw its 5-day average volume 0.75 million, a negative change from its year-to-date volume of 0.96 million. As of the previous 9 days, the stock’s Stochastic %D was 44.84%. Additionally, its Average True Range was 1.23.
During the past 100 days, Denali Therapeutics Inc’s (DNLI) raw stochastic average was set at 14.92%, which indicates a significant decrease from 15.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 55.05% in the past 14 days, which was lower than the 60.90% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $21.90, while its 200-day Moving Average is $23.69. Nevertheless, the first resistance level for the watch stands at $21.63 in the near term. At $22.52, the stock is likely to face the second major resistance level. The third major resistance level sits at $23.00. If the price goes on to break the first support level at $20.26, it is likely to go to the next support level at $19.78. The third support level lies at $18.89 if the price breaches the second support level.
Denali Therapeutics Inc (NASDAQ: DNLI) Key Stats
There are currently 143,922K shares outstanding in the company with a market cap of 2.98 billion. Presently, the company’s annual sales total 330,530 K according to its annual income of -145,220 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -107,190 K.
